Key Points Medicare and Medicaid have been overpaying Quest Diagnostics for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%. And they might keep cutting rates for two more years. These 10 stocks could mint the next wave of millionaires › Medical testing giant Quest Diagnostics (NYSE: DGX) stock slipped 5.1% through 11:30 a.m. Tuesday, after the Centers for Medicare & Medicaid Services (CMS) disclosed Monday that they've been paying about 16% more for lab work than private insurers pay. No longer. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.